Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum

Liu,Ya‑Ping; Hu,Guo‑Fu; Wu,Yun‑Xia

doi:10.3892/ol.2015.3227

Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum

Authors:
- Ya‑Ping Liu
- Guo‑Fu Hu
- Yun‑Xia Wu
View Affiliations

Affiliations: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
Published online on: May 19, 2015 https://doi.org/10.3892/ol.2015.3227
Pages: 137-142
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hormone therapy is the most commonly used treatment for prostate cancer, but for androgen‑independent cancer, few effective treatment methods are available. Therefore, the requirement to develop novel and effective anti‑prostate cancer drugs is extremely urgent. Angiogenin has been suggested as a molecular target for prostate cancer treatment; its overexpression contributes to androgen‑dependent prostate cancer growth and castration‑resistant growth of androgen‑independent prostate cancer. The aim of the present study was to investigate whether neamine, a low toxicity angiogenin nuclear translocation inhibitor, has preferential anti‑prostate cancer activity compared with cis‑platinum (DDP) and the mechanisms involved. Immunofluorescence and MTT assays were used to observe the effect of neamine on the nuclear translocation of angiogenin and cell proliferation, and a PC‑3 cell transplanted tumor model was used to investigate the in vivo activity of neamine and DDP. Immunohistochemistry was performed to observe the expression of angiogenin, cluster of differentiation (CD)31 and Ki‑67. It was found that neamine blocked nuclear translocation of angiogenin effectively and inhibited angiogenin‑induced human umbilical vein endothelial cell and PC‑3 cell proliferation in a dose‑dependent manner. Neamine exerted a comparative antitumor effect, but lower toxicity (weight loss), in the PC‑3 xenograft models treated with DDP. Neamine consistently reduced the expression of angiogenin and CD31 significantly, but no difference was found in Ki-67 expression compared with DDP. These data suggested that neamine may be a promising agent for prostate cancer treatment.

View Figures

View References

1	Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Santos AF, Huang H and Tindall DJ: The androgen receptor: A potential target for therapy of prostate cancer. Steroids. 69:79–85. 2004. View Article : Google Scholar : PubMed/NCBI
4	Izawa JI and Dinney CP: The role of angiogenesis in prostate and other urologic cancers: A review. CMAJ. 164:662–670. 2001.PubMed/NCBI
5	Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP and Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 157:2329–2333. 1997. View Article : Google Scholar : PubMed/NCBI
6	Wikström P, Bergh A and Damber JE: Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol. 34:85–94. 2000. View Article : Google Scholar : PubMed/NCBI
7	Acevedo VD, Gangula RD, Freeman KW, et al: Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 12:559–571. 2007. View Article : Google Scholar : PubMed/NCBI
8	Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M and Härkönen P: Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 29:23–28. 2001. View Article : Google Scholar : PubMed/NCBI
9	Fett JW, Strydom DJ, Lobb RR, et al: Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 24:5480–5486. 1985. View Article : Google Scholar : PubMed/NCBI
10	Moroianu J and Riordan JF: Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci USA. 91:1677–1681. 1994. View Article : Google Scholar : PubMed/NCBI
11	Kishimoto K, Liu S, Tsuji T, Olson KA and Hu GF: Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene. 24:445–456. 2005. View Article : Google Scholar : PubMed/NCBI
12	Bottero V, Sadagopan S, Johnson KE, Dutta S, Veettil MV and Chandran B: Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation. J Virol. 87:11806–11820. 2013. View Article : Google Scholar : PubMed/NCBI
13	Majumder PK, Yeh JJ, George DJ, et al: Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc Natl Acad Sci USA. 100:7841–7846. 2003. View Article : Google Scholar : PubMed/NCBI
14	Pina F, Botelho F, Lopes T, et al: Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening. Eur J Cancer Prev. 23:166–172. 2014. View Article : Google Scholar : PubMed/NCBI
15	Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA and Cheng L: Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res. 11:8358–8363. 2005. View Article : Google Scholar : PubMed/NCBI
16	Yoshioka N, Wang L, Kishimoto K, Tsuji T and Hu GF: A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA. 103:14519–14524. 2006. View Article : Google Scholar : PubMed/NCBI
17	Olson KA, Fett JW, French TC, Key ME and Vallee BL: Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA. 92:442–446. 1995. View Article : Google Scholar : PubMed/NCBI
18	Olson KA, French TC, Vallee BL and Fett JW: A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res. 54:4576–4579. 1994.PubMed/NCBI
19	Hu GF: Neomycin inhibits angiogenin-induced angiogenesis. Proc Natl Acad Sci USA. 95:9791–9795. 1998. View Article : Google Scholar : PubMed/NCBI
20	Zhao J, Wang YC, Yang LY, Yu DH, Pan PT and Wang L: Neamine inhibits cell proliferation, migration, and invasion in H7402 human hepatoma cells. Saudi Med J. 31:1309–1314. 2010.PubMed/NCBI
21	Kishimoto K, Yoshida S, Ibaragi S, Yoshioka N, Hu GF and Sasaki A: Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation. Anticancer Res. 34:2113–2121. 2014.PubMed/NCBI
22	Yuan Y, Wang F, Liu XH, Gong DJ, Cheng HZ and Huang SD: Angiogenin is involved in lung adenocarcinoma cell proliferation and angiogenesis. Lung Cancer. 66:28–36. 2009. View Article : Google Scholar : PubMed/NCBI
23	Hirukawa S, Olson KA, Tsuji T and Hu GF: Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. Clin Cancer Res. 11:8745–8752. 2005. View Article : Google Scholar : PubMed/NCBI
24	Majumdar MK and Majumdar SK: Isolation and characterization of three phosphoamido-neomycins and their conversion into neomycin by Streptomyces fradiae. Biochem J. 120:271–278. 1970.PubMed/NCBI
25	Deng SR, Li J, Zhang ZQ, et al: DS147 improves pregnancy in mice with embryo implantation dysfunction induced by controlled ovarian stimulation. J Huazhong Univ Sci Technolog Med Sci. 33:573–580. 2013. View Article : Google Scholar : PubMed/NCBI
26	Hirukawa S, Olson KA, Tsuji T and Hu GF: Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. Clin Cancer Res. 11:8745–8752. 2005. View Article : Google Scholar : PubMed/NCBI
27	Williams PD, Bennett DB, Gleason CR and Hottendorf GH: Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother. 31:570–574. 1987. View Article : Google Scholar : PubMed/NCBI
28	Au S, Weiner N and Schacht J: Membrane perturbation by aminoglycosides as a simple screen of their toxicity. Antimicrob Agents Chemother. 30:395–397. 1986. View Article : Google Scholar : PubMed/NCBI
29	Yang B and Wang JJ: Industry News: Avastin approved for metastatic colorectal cancer. Discov Med. 4:79–80. 2004.PubMed/NCBI